Clinical trial
Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome…
NCT00158730 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00158730 |
|---|---|
| Title | Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment |
| Official title | Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Invasive Aspergillosis, Other Fungal Infections |
| Intervention type | Drug |
| Interventions | AmBisome |
| Enrollment | 800 |
| Start date | Apr 1, 2003 |
| Completion | Jan 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 18, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: